Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXN407 in Diabetic Macular Oedema
NCT04565756Phase 2Completed
- Sponsor
- Foventa Therapeutics
- Start
- Nov 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EXN407 in diabetic macular edema (DME), sponsored by Foventa Therapeutics. Started Nov 2020; status: completed.
02
Drugs
EXN407
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04565756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565756.